Akari Therapeutics Announces $5M Financing Agreement

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potentialAkari Therapeutics ( (AKTX) ) has provided an announcement. Akari Therapeutics announced on December 16, 2025, that it entered into agreements to raise approximately $5 million through a registered direct offering and concurrent private placements of American Depositary Shares (ADSs) and warrants, with significant participation from company executives and institutional investors. The financing will support research and development, working capital, and corporate activities, while reducing its liabilities through a $2.50 million debt exchange into warrants, enhancing both financial flexibility and capital structure. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the offering. The most recent analyst rating on (AKTX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page. Spark’s Take on AKTX Stock According to Spark, TipRanks’ AI Analyst, AKTX is a Neutral. Akari Therapeutics’ stock score of 44 reflects significant challenges due to its current financial instability and lack of revenue. While the technical analysis indicates a neutral trend, the company’s speculative nature due to the absence of traditional valuation metrics underscores the risk. However, the recent positive corporate event with the appointment of a new CEO brings some potential for strategic improvement, slightly offsetting the otherwise high-risk profile. To see Spark’s full report on AKTX stock, click here. More about Akari Therapeutics Akari Therapeutics is an oncology biotechnology company specializing in developing innovative antibody drug conjugates (ADCs) using a proprietary payload platform. Its leading candidate, AKTX-101, targets the Trop2 receptor on cancer cells and applies a novel spliceosome modulator payload to disrupt RNA splicing within cancer cells while activating immune responses. Average Trading Volume: 738,377 Technical Sentiment Signal: Sell Current Market Cap: $8.27M